Genoptix Inc., a Carlsbad, Calif.-based provider of personalized medicine services for management of hematolymphatic disorders, raised $85 million in its IPO. The company priced five million common shares at $17 per share ($14-$16 range), for an initial market cap of approximately $265 million. It will trade on the Nasdaq under ticker symbol GXDX, while Lehman Brothers served as lead underwriter.
Genoptix had raised around $49 million in VC funding since 1999, from firms like Enterprise Partners, Chicago Growth Partners, William Blair Capital Partners, Alliance Technology Ventures, Tullis-Dickerson and Excelsior Venture Partners. www.genoptix.com